DelveInsight’s, “Mantle Cell Lymphoma Pipeline Insight, 2025” report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Mantle Cell Lymphoma pipeline landscape. It covers the Mantle Cell Lymphoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Mantle Cell Lymphoma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Click here to explore the therapies and trials making headlines @ https://www.delveinsight.com/sample-request/mantle-cell-lymphoma-pipeline-insight

Key Takeaways from the Mantle Cell Lymphoma Pipeline Report

• On February 06, 2026- BeOne Medicines announced a study is to compare how well sonrotoclax plus zanubrutinib works versus zanubrutinib plus placebo in treating adults with relapsed/refractory (R/R) mantle cell lymphoma (MCL). This study will also look at the safety of sonrotoclax plus zanubrutinib versus zanubrutinib plus placebo.
• On February 06, 2026- Guangzhou Lupeng Pharmaceutical Company Ltd. initiated a a Phase 3, randomized, open-label study comparing Rocbrutinib versus investigator’s choice of BTK inhibitor (ibrutinib, acalabrutinib, zanubrutinib, or orelabrutinib) in patients with MCL who have received at least one prior line of therapy and are naïve to BTK inhibitor treatment (except for intolerance).
• DelveInsight’s Mantle Cell Lymphoma Pipeline report depicts a robust space with 20+ active players working to develop 22+ pipeline therapies for Mantle Cell Lymphoma treatment.
• The leading Mantle Cell Lymphoma Companies such as AbbVie, Takeda, PharmaEngine, InnoCare Pharma Inc., Guangzhou Lupeng Pharmaceutical Company LTD., BeiGene, Gilead Sciences, and others.
• Promising Mantle Cell Lymphoma Therapies such as Lenalidomide, Obinutuzumab, Glofitamab, Ibrutinib, Rituximab, Pirtobrutinib, Acalabrutinib, and others.

Want to know which companies are leading innovation in Mantle Cell Lymphoma? @ Mantle Cell Lymphoma Clinical Trials Assessment

The Mantle Cell Lymphoma Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Mantle Cell Lymphoma Pipeline Report also highlights the unmet needs with respect to the Mantle Cell Lymphoma.

Mantle Cell Lymphoma Overview

Mantle cell lymphoma (MCL) is a rare subtype of B-cell non-Hodgkin lymphomas (NHLs) characterized by an (11,14) translocation resulting in overexpression of the cyclin D1 (CCND1) gene. The variety of morphologic variants may make this a challenging diagnosis, although some cases are uncomplicated. Many individuals with mantle cell lymphoma may not have symptoms (asymptomatic) during early stages of the disease. However, affected individuals may eventually seek medical attention due to persistent, usually painless, swelling of certain lymph nodes, particularly nodes within the neck and throat region (e.g., Waldeyer’s ring).

Mantle Cell Lymphoma Emerging Drugs

• Venetoclax: AbbVie

Venetoclax is a first-in-class medicine that selectively binds and inhibits the B-cell lymphoma-2 (BCL-2) protein. In some blood cancers, BCL-2 prevents cancer cells from undergoing their natural death or self-destruction process, called apoptosis. VENCLYXTO targets the BCL-2 protein and works to help restore the process of apoptosis.

Venetoclax is being developed by AbbVie and Roche. It is jointly commercialized by AbbVie and Genentech, a member of the Roche Group, in the US and by AbbVie outside of the US. Together, the companies are committed to BCL-2 research and to studying venetoclax in clinical trials across several blood and other cancers. Venetoclax is approved in more than 80 countries, including the US. Currently the product is in Phase III for mantle cell lymphoma.

• Ixazomib: Takeda

Ixazomib belongs to a class of drugs called proteasome inhibitors, which work by blocking the action of proteasomes, cellular structures responsible for breaking down proteins. By inhibiting proteasomes, ixazomib helps to disrupt the growth and survival of cancer cells. Currently, the product is in the Phase II stage of its development for the treatment of mantle cell lymphoma.

• LP-168: Jiangsu Hansoh Pharmaceutical

LP-168 is a novel drug candidate being explored for the treatment of Mantle Cell Lymphoma (MCL), a rare and aggressive form of non-Hodgkin lymphoma. It is an oral selective inhibitor of Bruton’s tyrosine kinase (BTK), which plays a key role in B-cell malignancies. By inhibiting BTK, LP-168 aims to block the survival and proliferation of cancerous B cells, offering a potential therapeutic option for patients with MCL. Early trials suggest promising efficacy, especially in patients who have relapsed or are resistant to current treatments. Currently, the drug is being developed in the Phase II stage of its development for the treatment Mantle Cell Lymphoma.

• PEP07: PharmaEngine

PEP07 is a checkpoint kinase 1 (CHK1) inhibitor which targets the DNA Damage Response (DDR) pathway. CHK1 inhibitors have important functions in the cell’s DDR process as it can enhance the damaging effect of cytotoxic therapy on DNA and prevent the self-repair of tumor cells leading to tumor cell deaths. Compared to other competitors targeting the DDR pathway, PEP07 has features such as high kinase selectivity, brain penetrating and oral bioavailability. PEP07 also has demonstrated significant single-agent activity and combination potential with standard treatments in preclinical models. PharmaEngine exercised the option for a Worldwide Exclusive License Agreement for PEP07 from UK-based Sentinel Oncology in September 2022. Currently, the drug is being developed in the Phase I stage of its development for the treatment Mantle Cell Lymphoma.

If you’re tracking ongoing Mantle Cell Lymphoma Clinical trials, this press release is a must-read @ Mantle Cell Lymphoma Treatment Drugs

The Mantle Cell Lymphoma Pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Mantle Cell Lymphoma with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Mantle Cell Lymphoma Treatment.
• Mantle Cell Lymphoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Mantle Cell Lymphoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Mantle Cell Lymphoma market.

Mantle Cell Lymphoma Companies

AbbVie, Takeda, PharmaEngine, InnoCare Pharma Inc., Guangzhou Lupeng Pharmaceutical Company LTD., BeiGene, Gilead Sciences and others.

Mantle Cell Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Mantle Cell Lymphoma Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

From emerging drug candidates to competitive intelligence, the Mantle Cell Lymphoma Pipeline Report covers it all @ Mantle Cell Lymphoma Market Drivers and Barriers, and Future Perspectives

Scope of the Mantle Cell Lymphoma Pipeline Report

• Coverage- Global
• Mantle Cell Lymphoma Companies- AbbVie, Takeda, PharmaEngine, InnoCare Pharma Inc., Guangzhou Lupeng Pharmaceutical Company LTD., BeiGene, Gilead Sciences and others.
• Mantle Cell Lymphoma Therapies- Lenalidomide, Obinutuzumab, Glofitamab, Ibrutinib, Rituximab, Ibrutinib, Pirtobrutinib, Acalabrutinib, and others.
• Mantle Cell Lymphoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Mantle Cell Lymphoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Discover what’s next for the Mantle Cell Lymphoma treatment landscape in this detailed analysis @ Mantle Cell Lymphoma Emerging Drugs and Major Players

Table of Contents

1. Introduction
2. Executive Summary
3. Mantle Cell Lymphoma: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Mantle Cell Lymphoma– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Venetoclax: AbbVie
9. Mid Stage Products (Phase II)
10. Ixazomib: Takeda
11. Early Stage Products (Phase I)
12. PEP07: PharmaEngine
13. Preclinical and Discovery Stage Products
14. Product Name: Company Name
15. Inactive Products
16. Mantle Cell Lymphoma Key Companies
17. Mantle Cell Lymphoma Key Products
18. Mantle Cell Lymphoma- Unmet Needs
19. Mantle Cell Lymphoma- Market Drivers and Barriers
20. Mantle Cell Lymphoma- Future Perspectives and Conclusion
21. Mantle Cell Lymphoma Analyst Views
22. Mantle Cell Lymphoma Key Companies
23. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/mantle-cell-lymphoma-pipeline-insight